CYNK-001 is a cell therapy commercialized by Celularity, with a leading Phase I program in Non-Hodgkin Lymphoma. According to Globaldata, it is involved in 10 clinical trials, of which 2 were completed, 4 are ongoing, 2 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of CYNK-001’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for CYNK-001 is expected to reach an annual total of $20 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Taniraleucel (CYNK-001, PNK-007) is under development for the treatment of malignant glioma, multiple myeloma, newly diagnosed primary or secondary acute myeloid leukemia, acute myelogenous leukemia, myelodysplastic syndrome, refractory acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), relapsed chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML) and Hodgkin's lymphoma and relapsed and refractory acute myeloid leukemia. It is administered through intravenous and intratumor routes. The therapeutic candidate constitutes umbilical cord blood-derived, culture-expanded unmodified NK cells. The drug candidate is also under development for the treatment and prevention of coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome. The drug candidate is being developed based on Impact (Immuno-Modulatory Placenta-derived Allogeneic Cell Therapy) technology. It was under development for recurrent glioblastoma multiforme.
Celularity is a biotechnology company that develops and commercializes therapeutics derived from the placenta for autoimmune and degenerative diseases, immuno-oncology, and functional regeneration. The company’s pre-clinical and clinical assets include CAR-T cell receptor and CAR-NK products; and functional regeneration products for wounds, burns, orthopedic, and other surgical indications. It also provides cord blood and placental blood and tissue biosourcing options. Celularity harnesses allogeneic placental cell platform to develop its product portfolio. The company’s products find application in the treatment of acute myeloid leukemia, crohn’s disease, diabetic peripheral neuropathy, and oral and aesthetic tissue repair among others. Celularity is headquartered in Warren, New Jersey, the US.
The company reported revenues of (US Dollars) US$21.3 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$109.1 million in FY2021, compared to an operating loss of US$4.2 million in FY2020. The net loss of the company was US$100.1 million in FY2021, compared to a net loss of US$2.6 million in FY2020. The company reported revenues of US$4.1 million for the third quarter ended September 2022, an increase of 9.5% over the previous quarter.
For a complete picture of CYNK-001’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.